Navigation Links
Brookhaven Lab and BioSET Inc. patent improved growth factor technology
Date:7/13/2010

UPTON, NY Brookhaven Science Associates, the company that manages the U.S. Department of Energy's Brookhaven National Laboratory, and Biosurface Engineering Technologies, Inc. (BioSET) of Rockville, Maryland, have been issued a U.S. patent for an improved second-generation technology for designing synthetic peptides that are important for tissue regeneration. These bioactive peptides are designed to communicate growth signals to cells of damaged tissue in order to foster efficient, rapid healing.

BioSET has an exclusive license for producing these peptides, which hold promise for improving the body's healing response in numerous applications of tissue repair. Developed at Brookhaven Lab, these synthetic peptides, known as growth factor analogs, are easier to produce than natural growth factors or growth factors derived from recombinant techniques.

Tom Rouech, BioSET's president, said, "This newly patented technology builds upon our core method for making synthetic biomimedic peptides that we developed with Brookhaven Lab scientists almost a decade ago. We can now make peptides in higher yields, with more purity, and more cost-effectively than we had done previously."

Louis Pea, the principal researcher at Brookhaven Lab who developed the technology with BioSET, added, "This new platform technology will allow us to make multiple variations of peptides, which can lead to numerous applications in tissue repair. For example, bandages can be designed with growth factor analogs to apply to wounds, or coatings for surgical implants can be made for better localized healing. I'm glad that this technology has progressed so well and may benefit many people with soft-tissue injuries." A soft tissue injury results from damage to muscles, ligaments, or tendons.

BioSET has sublicensed the newly patented technology to Tornier, Inc., a global orthopedic company, to develop synthetic peptides for sports medicine applications, with emphasis on rotator cuff, shoulder, knee, and elbow injuries. The company will develop novel soft-tissue grafts with synthetic human growth factor for orthopedic markets.

"Assessing the role of tissue regeneration and clinical testing of the new growth factor analogs is the next step as we bring these important new treatments to surgeons and their patients," Rouech said. "A previously patented growth factor analog, B2A, designed to improve bone repair, is currently in clinical trials for spinal fusion of the lower back and we remain very encouraged by the early results of these studies."

The U.S. Department of Energy's Office of Science, the National Institutes of Health, and BioSET funded the initial research to develop this growth factor technology. One of three patents related to this technology issued to BSA and BioSET, the new patent (US 7,700,563 B2), was issued on April 20, 2010.


'/>"/>

Contact: Diane Greenberg
greenb@bnl.gov
631-344-2347
DOE/Brookhaven National Laboratory
Source:Eurekalert

Related medicine news :

1. USF receives patent for technology to improve treatment for neurodegenerative diseases
2. Quincy Bioscience Receives Patent for Jellyfish Protein Aequorin
3. Greenway Awarded U.S. Patent For EHR Functionality and Workflow
4. Volumetrics Medical Imaging, LLC and Medison Co., Ltd. Announce Technology License and Settlement of Patent Litigation
5. Mobile and Patented: DATA-TO-CAMERA TOGGLE on handheld device replaces old camera and clipboard approach everywhere! Beats IPAD to camera punch too.....
6. US Patent Granted To Chrono Therapeutics Inc. For Its Chrono-Pharmacological Drug Delivery Systems And Applications
7. GenomeQuest Upgrades Online Patent Searching
8. "IPGDx, LLC Announces The Continued Validation Of Its Patented Technology For The Assessment Of Prognosis; PrognostiCheck" Getting the New Information to Patients and Do
9. Drug Patents in India Helping Promote Innovation
10. Innovative Patent-pending Shapewear Technology Introduced for Jeans.
11. Wind Power Systems, LLC (WPS) Launches PPM to Raise $2.5M for Earth Friendly Patent Pending "Small Wind" Turbine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... PA (PRWEB) , ... July 24, 2017 , ... Summer ... rain storms wreak havoc across communities and often result in massive tree damage requiring ... actions homeowners can take now including tree trimming, tree cabling and hazardous tree removal. ...
(Date:7/24/2017)... Falls Church, VA (PRWEB) , ... July 24, ... ... is figuring out how to change manufacturers future. , The agency is hammering ... Century Cures Act, one of the farthest-ranging laws ever to affect FDA-regulated firms. ...
(Date:7/24/2017)... ... July 24, 2017 , ... Advanced Dermatology, ... Bellmore, New York, (516) 784-5858. The office opened earlier this summer and is ... Friedman and Fruma Leah Wiederman. , Advanced Dermatology, P.C. founder and medical ...
(Date:7/24/2017)... ... 24, 2017 , ... “Nana Nana Boo Boo”: a delightful tale of a ... “Nana Nana Boo Boo” is the creation of published author Michael Rush, a Deputy ... Faith Publishing, Michael Rush’s new book presents the importance of manners in a way ...
(Date:7/24/2017)... ... ... “Journey to the Light: The Quest for Happiness and Love. . . ... finding herself. “Journey to the Light: The Quest for Happiness and Love. . ... of newsletters, manuals, and articles, who has recently decided to expand her literary horizons ...
Breaking Medicine News(10 mins):
(Date:7/5/2017)... Pace Analytical, a company of over 2,000 employees and a leader in environmental ... Sciences, further solidifying their position as the top American owned and operated environmental ... ... Analytical ... Mt Juliet, TN , enhances Pace Analytical,s capability as an innovative full ...
(Date:6/30/2017)... June 30, 2017 In vitro diagnostics market ... of May, at least ten diagnostic companies have successfully ... public offerings and a loan facility.  The size of ... $80 million.  Kalorama Information provides a monthly IVD ... Diagnostics Knowledge Center. ...
(Date:6/27/2017)... June 27, 2017  Therapix Biosciences Ltd. (Nasdaq: ... specializing in the development of cannabinoid-based drugs, today announced ... Opening Bell in New York, NY ... its initial public offering (IPO) of American Depository Shares ... 2017. Dr. Elran Haber, Ph.D., Chief Executive ...
Breaking Medicine Technology: